Werner Markus Enz

MiniNaviDent AG develops dental equipment. It develops miniaturized navigation system, which is directly fitted to the surgical handpiece, and which guides the drill in real-time and in 3D to the correct implant position and angle using a ceramic dual-mode-marker and proprietary algorithms. The company was founded in 2013 by Frank Berlinghoff, Philipp Jürgens, Hans-Florian Zeilhofer and Erik Schkommodau and is headquartered in Basel, Switzerland.

ErfindungsVerwertung AG engages in the provision of seed capital as well as consulting and market research services to startup companies in the field of life sciences. It offers project and business plan reviews, financial planning, business set-up, coaching, and assistance to find venture capital. The firm supports life sciences researchers, initiators of university projects, developers, and inventors in the field of drug development, medical technology, diagnostics, biomedicine, and nanotechnology. The company was founded in 1996 and is headquartered in Basel, Switzerland.

INOFEA AG is a Swiss biotech company founded in 2014 that works closely with its clients to provide them with a complex line of services that sustain their processes and products. The company is based in Muttenz, Switzerland. The company has developed a patented platform technology called enzzen® that empowers enzymes to fit industrial applications. Enzymes are protein molecules that carry a vital energy factor needed for every chemical reaction and reactions that occur in any living organism. INOFEA has successfully demonstrated the added-value of their technology for enzyme-mediated bioconjugation or post-translational modifications of antibodies or other large molecules. Anne Timm has been the CEO of the company since 2018.

Perseo pharma AG is a Swiss preclinical stage biopharmaceutical company that focuses on discovering and developing enzyme therapeutics for the treatment of digestive diseases. The company is based in Muttenz, Switzerland. The company has entered into a strategic research and development collaboration with Nestlé Health Science to develop novel therapies for digestive diseases. Perseo pharma's innovative technology is based on therapeutic enzymes that are protected in a nano shield with muco-adhesive coating. The company is a spin-off from the University of Applied Sciences (FHNW), School of Life Sciences in Switzerland, and was founded by Prof. Dr. Patrick Shahgaldian. Yves Dudal has been the CEO of the company since 2019.

Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland.